in the absence of a submission from the holder of the marketing authorisation:
cemiplimab (Libtayo®) is not recommended for use within NHSScotland.
Indication under review: As monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)expressing PD-L1 (in ≥50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:
- locally advanced NSCLC who are not candidates for definitive chemoradiation, or
- metastatic NSCLC
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice623KB (PDF)
Medicine details
- Medicine name:
- cemiplimab (Libtayo)
- SMC ID:
- SMC2489
- Indication:
As monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)expressing PD-L1 (in ≥50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:
• locally advanced NSCLC who are not candidates for definitive chemoradiation, or
• metastatic NSCLC- Pharmaceutical company
- Sanofi
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 May 2022